Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder

Journal of Psychiatric Research

Volumn 47, Issue 10, 2013, Pages 1343-1348

  Lee, Sheng Yu ^a   Chen, Shiou Lan ^a   Chang, Yun Hsuan ^b   Chen, Po See ^a   Huang, San Yuan ^c   Tzeng, Nian Sheng ^c   Wang, Yu Shan ^a   Wang, Liang Jen ^d   Lee, I Hui ^a   Yeh, Tzung Lieh ^a   Yang, Yen Kuang ^a   Lu, Ru Band ^a,b   Hong, Jau Shyong ^e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Bipolar II disorder; HDL C; Memantine; Treatment

Indexed keywords

MEMANTINE; PLACEBO; VALPROIC ACID;

ADD ON THERAPY; ARTICLE; BIPOLAR II DISORDER; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

BIPOLAR II DISORDER; HDL-C; MEMANTINE; TREATMENT;

ADULT; ANALYSIS OF VARIANCE; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, HDL; MALE; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; VALPROIC ACID; YOUNG ADULT;

EID: 84881541644     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.06.017     Document Type: Article

References (67)

1. Akiskal H.S., Djenderedjian A.M., Rosenthal R.H., Khani M.K. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. American Journal of Psychiatry 1977, 134:1227-1233.
2. Akiskal H.S., Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatric Clinics of North America 1999, 22:517-534. vii.
3. Akiskal H.S., Rosenthal R.H., Rosenthal T.L., Kashgarian M., Khani M.K., Puzantian V.R. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Archives of General Psychiatry 1979, 36:635-643.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorder-IV-TR 2000, American Psychiatric Association, Washington. 4th ed.
5. American Psychiatric Association Diagnostic and statistical manual of mental disorder-IV-TR 2002, American Psychiatric Association, Washington. 4th ed.
6. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. Journal of Affective Disorders 1998, 50:143-151.
7. Angst J. The bipolar spectrum. British Journal of Psychiatry 2007, 190:189-191.
8. Angst J., Gamma A., Sellaro R., Lavori P.W., Zhang H. Recurrence of bipolar disorders and major depression. A life-long perspective. European Archives of Psychiatry and Clinical Neuroscience 2003, 253:236-240.
9. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002, 46:176-179.
10. Bauer M., Unutzer J., Pincus H.A., Lawson W.B. Bipolar disorder. Mental Health Services Research 2002, 4:225-229.
11. Benazzi F. Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients. Journal of Affective Disorders 2001, 66:13-18.
12. Benazzi F. Is 4 days the minimum duration of hypomania in bipolar II disorder?. European Archives of Psychiatry and Clinical Neuroscience 2001, 25:32-34.
13. Benazzi F., Akiskal H.S. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. Journal of Affective Disorders 2003, 73:33-38.
14. Beyer J.L., Krishnan K.R. Volumetric brain imaging findings in mood disorders. Bipolar Disorders 2002, 4:89-104.
15. Bjorkhem I., Cedazo-Minguez A., Leoni V., Meaney S. Oxysterols and neurodegenerative diseases. Molecular Aspects of Medicine 2009, 30:171-179.
16. Brennan B.P., Roberts J.L., Fogarty K.V., Reynolds K.A., Jonas J.M., Hudson J.I. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. International Journal of Eating Disorders 2008, 41:520-526.
17. Buchner A., Faul F., Erdfelder E. G-Power: a priori, post hoc, and compromise power analyses for the Macintosh 1996, Version 2.1.1. ed., University of Trier, Trier, Germany.
18. Burke W.J., Wengel S.P. Late-life mood disorders. Clinics in Geriatric Medicine 2003, 19:777-797. vii.
19. Cassidy F., Carroll B.J. Seasonal variation of mixed and pure episodes of bipolar disorder. Journal of Affective Disorders 2002, 68:25-31.
20. Chander R., Kapoor N.K. High density lipoprotein is a scavenger of superoxide anions. Biochemical Pharmacology 1990, 40:1663-1665.
21. Chen H.H., Zhou J.F. Low cholesterol in erythrocyte membranes and high lipoperoxides in erythrocytes are the potential risk factors for cerebral hemorrhagic stroke in human. Biomedical and Environmental Sciences 2001, 14:189-198.
22. Chen S.L., Tao P.L., Chu C.H., Chen S.H., Wu H.E., Tseng L.F., et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. Journal of Neuroimmune Pharmacology 2012, 7(2):444-453.
23. Choi D.W. Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke 1990, 21:III20-III22.
24. Drevets W.C., Price J.L., Simpson J.R., Todd R.D., Reich T., Vannier M., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
25. Endicott J., Spitzer R.L. Adiagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry 1978, 35:837-844.
26. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders 2005, 7:424-430.
27. Faul F., Erdfelder E., Buchner A., Lang A. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behavior Research Methods 2009, 41:1149-1160.
28. Ferguson J.M., Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clinical Neuropharmacology 2007, 30:136-144.
29. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. American Journal of Cardiology 2001, 88:9N-13N.
30. Ghaemi S.N., Shields G.S., Hegarty J.D., Goodwin F.K. Cholesterol levels in mood disorders: high or low?. Bipolar Disorders 2000, 2:60-64.
31. Hamilton M. Arating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
32. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967, 6:278-296.
33. Hermanussen M., Tresguerres J.A. Anew anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Economics and Human Biology 2005, 3:329-337.
34. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcoholism Clinical and Experimental Research 2004, 28:374-384.
35. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Maser J., Rice J.A., et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders?. Journal of Affective Disorders 2003, 73:19-32.
36. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Leon A.C., Solomon D.A., et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry 2005, 62:1322-1330.
37. Keck P.E., Hsu H.A., Papadakis K., Russo J. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clinical Neuropharmacology 2009, 32:199-204.
38. Koukopoulos A., Reginaldi D., Serra G., Sani G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disorders 2010, 12:348-349.
39. Koukopoulos A., Serra G., Koukopoulos A.E., Reginaldi D. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. Journal of Affective Disorders 2012, 136:163-166.
40. Kowatch R.A., Fristad M., Birmaher B., Wagner K.D., Findling R.L., Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:213-235.
41. Launer L.J., White L.R., Petrovitch H., Ross G.W., Curb J.D. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001, 57:1447-1452.
42. Maes M., Smith R., Christophe A., Vandoolaeghe E., Van Gastel A., Neels H., et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatrica Scandinavica 1997, 95:212-221.
43. Oxenkrug G.F., Branconnier R.J., Harto-Truax N., Cole J.O. Is serum cholesterol a biological marker for major depressive disorder?. American Journal of Psychiatry 1983, 140:920-921.
44. Pae C.U., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Aberration of cholesterol level in first-onset bipolar I patients. Journal of Affective Disorders 2004, 83:79-82.
45. Pallanti S., Quercioli L., Pazzagli A., Rossi A., Dell'Osso L., Pini S., et al. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. American Journal of Psychiatry 1999, 156:1094-1096.
46. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61:199-205.
47. Paterno R., Ruocco A., Postiglione A., Hubsch A., Andresen I., Lang M.G. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovascular Diseases 2004, 17:204-211.
48. Popik P., Kos T., Zhang Y., Bisaga A. Memantine reduces consumption of highly palatable food in a rat model of binge eating. Amino Acids 2011, 40:477-485.
49. Quan M.N., Zhang N., Wang Y.Y., Zhang T., Yang Z. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience 2011, 182:88-97.
50. Rogoz Z., Skuza G., Maj J., Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002, 42:1024-1030.
51. Sacco R.L., Benson R.T., Kargman D.E., Boden-Albala B., Tuck C., Lin I.F., et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001, 285:2729-2735.
52. Sagud M., Mihaljevic-Peles A., Pivac N., Jakovljevic M., Muck-Seler D. Platelet serotonin and serum lipids in psychotic mania. Journal of Affective Disorders 2007, 97:247-251.
53. Sagud M., Mihaljevic-Peles A., Pivac N., Jakovljevic M., Muck-Seler D. Lipid levels in female patients with affective disorders. Psychiatry Research 2009, 168:218-221.
54. Sani G., Serra G., Kotzalidis G.D., Romano S., Tamorri S.M., Manfredi G., et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012, 26:663-690.
55. Schaefer M., Leopold K., Hinzpeter A., Heinz A., Krebs M. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007, 40:149-151.
56. Schiffer H.H. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. Molecular Neurobiology 2002, 25:191-212.
57. Stoll A.L., Renshaw P.F., Yurgelun-Todd D.A., Cohen B.M. Neuroimaging in bipolar disorder: what have we learned?. Biological Psychiatry 2000, 48:505-517.
58. Tsapakis E.M., Travis M.J. Glutamate and psychiatric disorders. Advances in Psychiatric Treatment 2002, 8:189-197.
59. Vieta E., Gastó C., Otero A., Nieto E., Vallejo J. Differential features between bipolar I and bipolar II disorder. Comprehensive Psychiatry 1997, 38:98-101.
60. Vieta E., Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disorders 2008, 10:163-178.
61. Wannamethee S.G., Shaper A.G., Ebrahim S. HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000, 31:1882-1888.
62. Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34:2344-2357.
63. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry 2005, 66(Suppl.5):40-48.
64. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. Arating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978, 133:429-435.
65. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. Arandomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
66. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., et al. Adouble-blind, placebo-controlled study of memantine in the treatment of major depression. The American Journal of Psychiatry 2006, 163:153-155.
67. Zeger S.L., Liang K.Y., Albert P.S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988, 44:1049-1060.